DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Calibrate is a 12-month program combining GLP-1 medication, coaching, and lifestyle interventions.
Solid GLP-1 coaching wrapper, but you pay for the structure
Calibrate is worth it if you want a GLP-1 prescription plus structured human coaching and habit-change education, and you have insurance likely to cover the drug. The medication does most of the heavy lifting; Calibrate's value is the wraparound support and a money-back weight-loss guarantee. It is poor value if you mainly want the cheapest path to medication, since the $199/month coaching fee sits on top of drug and lab costs and is not reimbursable by insurance.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Independent third-party ratings, shown for context. Not affiliated with HealthVetted scoring.
Calibrate (operated by Calibrate Health, Inc., based in New York) is a "metabolic health" program built around the idea that durable weight loss requires both an effective medication and sustained behavioral support. Rather than selling supplements or compounded drugs, Calibrate functions as a clinician-and-coach layer that sits on top of the established GLP-1 medication class.
The onboarding sequence is consistent across reviews and the company's own materials:
The medication itself is the engine. Calibrate clinicians prescribe FDA-approved GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic), liraglutide (Saxenda), or the GIP/GLP-1 dual agonist tirzepatide (Zepbound, Mounjaro). Critically, Calibrate does not dispense or compound the drug. It writes a prescription that you fill through a regular pharmacy, billed through your own insurance. The program fee buys the clinical oversight, coaching, and insurance-navigation help — not the medicine.
This is the single most important structural fact about Calibrate, and the one most often glossed over: you are paying Calibrate for coaching and access logistics, while paying separately (through insurance, ideally) for the thing that actually drives the weight loss.
GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after eating. They work through several mechanisms documented in the FDA labeling and clinical literature: they slow gastric emptying, enhance glucose-dependent insulin secretion, and act on appetite-regulating centers in the brain to reduce hunger and food "noise." The net effect is reduced caloric intake without the constant willpower battle of conventional dieting.
Tirzepatide (Zepbound/Mounjaro) adds a second mechanism — it also activates the GIP receptor — which appears to produce greater average weight loss than GLP-1 activation alone.
Calibrate's behavioral curriculum is built on a real clinical insight: medication suppresses appetite, but it does not by itself teach the food, sleep, activity, and stress habits that determine whether weight stays off. The intensive lifestyle intervention model Calibrate borrows from has strong precedent — the Diabetes Prevention Program (NIH/NIDDK) and Look AHEAD trial both established that structured lifestyle coaching produces meaningful, if modest, metabolic benefit. Pairing that with a potent medication is a reasonable, evidence-aligned design.
This is where you need to separate two different bodies of evidence.
The medications Calibrate prescribes are backed by large, randomized, placebo-controlled trials published in top journals:
So the *tool* Calibrate uses is genuinely among the most effective non-surgical obesity treatments ever studied.
Calibrate has repeatedly reported strong outcomes for its members — figures in the range of roughly 14.8% to 16.2% average weight loss at 12 months, drawn from cohorts of thousands of members, with reported sustained or continued loss at 18–24 months and improvements in metabolic markers (e.g., a large share of members with diabetes or prediabetes returning HbA1c to normal range). The company has also published a four-year real-world analysis describing continued benefit over time.
These numbers are plausible and broadly consistent with what the medications achieve in trials. But two caveats matter for an honest read:
Calibrate's pricing is one of its weakest points relative to the current market. The program operates on a monthly membership model with an upfront commitment. As of early 2026, individual pricing starts at $199/month with an initial three-month minimum (about $597 to start), then continues month-to-month — a notable reduction from the $299/month it previously charged. Over a full year, the membership fee alone therefore runs to roughly $2,400, covering coaching, clinical visits, and the curriculum.
The crucial distinction: that fee does not include the medication. The drug and labs are billed through your insurance separately. Calibrate's value proposition leans heavily on the claim that it helps members secure insurance coverage so that GLP-1 copays land low (the company has cited copays around $25/month for many insured members after deductibles).
This creates a real risk to weigh:
Calibrate has offered a "Results" guarantee — not a full money-back promise but a 50% refund of membership fees if you do not achieve at least 10% weight loss after 12 consecutive membership months and you meet the eligibility criteria. Those conditions are strict (for example, you cannot have taken a prescription weight-loss medication in the 12 months before enrolling, you must adhere to the program's commitment from month two onward, and the refund excludes the cost of medication, labs, and third-party charges). As with all such guarantees the fine print matters, and members have reported difficulty with refunds (see below).
The clinical model is legitimate: real licensed clinicians, FDA-approved medications, prescriptions filled at standard pharmacies, and a behavior-change curriculum grounded in established obesity-medicine principles. This is meaningfully safer and more transparent than the gray market of compounded or unregulated "GLP-1" products, because you receive a branded, FDA-regulated drug.
Standard GLP-1 safety considerations apply (these come from the FDA labeling, not from Calibrate):
The bigger legitimacy concern with Calibrate is not clinical — it is operational and financial. The company went through significant turmoil: multiple rounds of layoffs in 2022–2023, and a 2023 restructuring in which private-equity lender Madryn Asset Management took a majority stake and the founder stepped down as CEO. During the GLP-1 supply shortages, Calibrate struggled to get members timely medication access, issued substantial refunds, and accumulated customer complaints (documented on the Better Business Bureau and consumer-review sites) around billing, medication delays, and difficulty obtaining promised refunds.
For a prospective member, the practical reading is: the medicine is safe and the clinical model is sound, but the *service reliability and billing experience* have been genuinely inconsistent, and you are signing a multi-month commitment with a company that has had financial stress.
Calibrate may be a reasonable fit if you:
You should probably skip Calibrate if you:
The telehealth GLP-1 landscape has expanded dramatically, and Calibrate's coaching-heavy, insurance-billed model now competes with several distinct approaches:
The honest competitive verdict: Calibrate's coaching and curriculum are legitimate and better-developed than many rivals', but you pay a premium for them, and that premium is only worth it if (a) you'll actually use the coaching and (b) insurance is covering your drug.
Calibrate is a real, clinically sound program built on the most effective non-surgical obesity treatments available — and the underlying medications are exceptionally well validated (STEP 1, SURMOUNT-1, both in NEJM). The reported member results of roughly 15% weight loss at one year are believable, but they are observational, company-reported, and very close to what the drugs achieve on their own, so the independent value of the coaching layer is real but unproven in a head-to-head sense.
The decision really comes down to economics and tolerance for risk. If your insurance covers GLP-1 medication and you want structured behavioral support, Calibrate can be a sensible, safe choice. If you have no drug coverage, or you mainly just want the prescription, the premium program fee is hard to justify when cheaper, more transparent telehealth options and your own physician can prescribe the identical medication. Layer on Calibrate's documented history of layoffs, ownership upheaval, medication-access problems, and refund complaints, and the prudent move is to confirm your insurance coverage in writing, read the guarantee fine print, and understand exactly what the multi-month commitment obligates you to before you enroll.
Calibrate is not a drug; it is a "Metabolic Reset" coaching program built around a GLP-1 prescription. A clinician reviews your intake and lab work and, when medically appropriate, prescribes a GLP-1 receptor agonist (such as semaglutide/Wegovy or tirzepatide/Zepbound). These medications mimic gut hormones that slow stomach emptying, reduce appetite, and quiet food cravings, so you tend to eat less. On top of the medication, Calibrate layers an app-based curriculum and a coach you meet roughly every two weeks via video, targeting four pillars: food, sleep, exercise, and emotional health. The intent is that the drug curbs hunger while the coaching builds habits meant to help sustain weight loss; durable results after stopping the medication are not guaranteed.
Active ingredient: Brand-name GLP-1
Calibrate's own outcomes reports describe average weight loss of about 16% of body weight at one year (N=37,031), rising to roughly 18% at year two (N=11,132), 20% at year three (N=2,461), and 21% at year four (N=620), with metabolic gains such as about 80% of members who started with diabetes or prediabetes reaching normal HbA1c within a year. Important caveat: these are company-reported, retrospective figures from Calibrate's internal database (its 2026 Results Report and conference presentations), not results from an independent peer-reviewed randomized controlled trial, and the shrinking sample sizes in later years reflect members who stayed enrolled (survivorship bias). The robust peer-reviewed evidence sits with the underlying medications: in the NEJM-published STEP 1 trial, semaglutide 2.4 mg produced about 14.9% average weight loss versus 2.4% for placebo over 68 weeks, and in the head-to-head SURMOUNT-5 trial tirzepatide produced about 20.2% versus semaglutide's 13.7% at 72 weeks. Calibrate's results are broadly consistent with those drug trials plus coaching, but should be read as program marketing data, not independent proof.
A realistic timeline of what Calibrate users typically experience. Individual results vary; this is educational, not medical advice.
You take Calibrate's online eligibility quiz, then complete required metabolic lab work, a waist measurement, and a comprehensive health-history intake. No medication yet — this is screening to confirm you're a clinically appropriate candidate.
You have a video visit with a board-certified clinician to review labs and medical history, and (if appropriate) are prescribed a GLP-1 such as semaglutide or tirzepatide. Medication is started at the lowest dose (e.g., semaglutide 0.25 mg or tirzepatide 2.5 mg weekly) to limit side effects.
Your first 1:1 coach session starts the official Calibrate year. Biweekly 15-minute coaching plus weekly lessons across food, sleep, exercise, and emotional health begin. Many people notice early appetite reduction within the first 1-2 weeks of medication; mild-to-moderate nausea or GI upset is common early and after each dose increase, usually easing as the body adapts.
The clinician steps the GLP-1 up roughly every 4 weeks toward a maintenance dose (semaglutide over ~16-20 weeks; tirzepatide over ~20-24 weeks). Appetite suppression typically becomes steadier through this window and gradual weight loss usually begins. GI side effects tend to be most noticeable in the days after each increase. Results vary, and some people slow or hold dose due to tolerability.
Once at a stable dose, weight loss continues more gradually alongside the behavior-change curriculum. In clinical trials, weight loss generally continues climbing toward a peak around months 6-12 (STEP 1: ~15% average at 68 weeks on semaglutide; SURMOUNT-1: ~20% at 72 weeks on tirzepatide). Calibrate offers a 10%-loss-in-a-year guarantee (terms apply); individual results differ widely.
The structured program is designed to build habits that outlast the year, but appetite and weight effects depend on continuing medication for most people — stopping a GLP-1 commonly leads to regain. Plateaus are normal, especially after the curve flattens past month 9-12. Ongoing clinician follow-up is needed to decide on dose, continuation, or a maintenance plan.
Side effects come from the GLP-1 medication, not the coaching. The most common are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion, usually worst when starting or increasing the dose and often easing over time. Less common but serious risks include pancreatitis, gallbladder problems (including gallstones), kidney injury from dehydration due to vomiting or diarrhea, and rare allergic reactions; severe or persistent abdominal pain warrants stopping the drug and seeking medical care. GLP-1s carry an FDA boxed warning for thyroid C-cell tumors seen in rodents (human relevance is unknown) and are contraindicated with a personal or family history of medullary thyroid cancer or MEN 2. Discuss any gallbladder, pancreas, kidney, eye, or mental-health history with the prescriber before starting.
Starts at $1990/mo from Calibrate.
As of 2026, Calibrate's membership runs about $199/month with a 3-month minimum (roughly $597 to start), covering 1:1 video coaching, the curriculum, a connected smart scale, app access, and insurance navigation. This fee is not reimbursed by insurance but is HSA/FSA eligible. Medication and lab costs are separate and billed through your insurance; members with commercial coverage often report GLP-1 copays around $25/month or less after meeting a deductible, but if your plan excludes GLP-1s for weight loss, out-of-pocket drug costs can run hundreds to over $1,000 per month. Calibrate offers a guarantee: members who do not lose at least 10% of body weight over 12 consecutive months may be eligible for 50% of their membership fees back. Budget for the membership plus uncertain medication costs, and confirm GLP-1 coverage before committing.
~$1,990 annual program fee + medication.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Calibrate combines real FDA-approved GLP-1 medications with coaching and a behavior-change curriculum, and reports strong average results (about 16% at one year). The catch: those figures are company-reported, not from a peer-reviewed randomized trial, and the $199/month coaching fee stacks on top of medication and lab costs billed through your insurance. Best for people who value structured support and can get their GLP-1 covered. Confirm coverage in writing before committing, and treat any results claim as a marketing figure rather than a guarantee.
Calibrate reports members lose an average of about 16% of body weight at one year, which is broadly consistent with what GLP-1 drug trials show. However, those figures are company-reported and retrospective rather than from an independent peer-reviewed trial, and results depend heavily on the prescribed medication and on staying with the program. Individual results vary, and weight regain is common if the medication is stopped without lasting habit change.
The Calibrate membership is about $199/month with a 3-month minimum (around $597 to start). That coaching fee is not covered by insurance but is HSA/FSA eligible. Medication and lab costs are billed separately through your insurance and are not included in the membership price.
Calibrate clinicians prescribe FDA-approved GLP-1 receptor agonists, most commonly semaglutide (such as Wegovy or Ozempic) or tirzepatide (Mounjaro or Zepbound), and in some cases other GLP-1 options like liraglutide (Saxenda). The specific drug is chosen by the clinician based on your health profile and insurance coverage; not every member is prescribed the same medication.
The $199/month membership fee itself is not covered by insurance, though you can pay with HSA/FSA funds. Your GLP-1 medication and lab work are billed through insurance separately, and coverage for the drug varies widely by plan. Confirm whether your plan covers GLP-1s for weight loss before you enroll, since some plans exclude them entirely.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, especially when starting or increasing the dose. Rare but serious risks include pancreatitis, gallbladder problems, and kidney injury from dehydration. GLP-1s also carry an FDA boxed warning for thyroid C-cell tumors (seen in rodents; human relevance unknown) and are contraindicated for those with a personal or family history of medullary thyroid cancer or MEN 2. Discuss your full medical history with the prescriber.
Calibrate requires a 3-month minimum commitment, after which membership renews monthly and can be cancelled. It offers a guarantee of 50% of membership fees back if you do not lose at least 10% of body weight over 12 consecutive months, but some customers report difficulty with cancellations and refunds in BBB and Trustpilot reviews, so read the current terms carefully before signing up.
Calibrate centers on a year-long structured coaching curriculum paired with a GLP-1 prescription and a 10% weight-loss guarantee, billing medication through your insurance. Medication-first services like Ro tend to emphasize fast prescribing, while Noom focuses on psychology-based coaching and now also offers GLP-1s; Calibrate sits between the two with more intensive 1:1 human coaching, which is reflected in its membership cost.
As with all GLP-1 programs, some weight regain is common after stopping the drug if eating and activity habits revert. Calibrate's curriculum is designed to build sustainable habits and includes a tapering plan intended to reduce regain, but maintaining results without medication is not guaranteed and varies by individual. Talk with your clinician before stopping or changing your medication.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Calibrate — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
Many brand-name drugs have a manufacturer copay-savings program on the drug’s official site. Check the maker’s website for a current savings card (commercial insurance usually required; government insurance excluded).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.